This page shows the latest Chiesi news and features for those working in and with pharma, biotech and healthcare.
Protalix Biotherapeutics and Chiesi Global Rare Diseases’s monthly treatment PRX-102 has demonstrated positive top-line results in a phase 3 trial evaluating the therapy in Fabry disease. ... Earlier this month, Protalix and Chiesi announced final
Moderna has agreed to separate deals with Vertex and Chiesi for research and development spanning cystic fibrosis (CF) therapies and pulmonary arterial hypertension (PAH). ... Prior to announcing the Vertex deal, Moderna revealed that it had come to a
Chiesi acquired Lamzede when it bought Zymenex in 2013 – the drug is administered weekly as intravenous infusions and the works by replacing the missing or malfunctioning enzyme. ... identify opportunities for us to collaborate in research and patient
First to market in Europe was Chiesi with its Trimbow (formoterol fumarate, glycopyrronium and beclomethasone) product, although this has to be administered twice-daily while Trelegy is dosed just once per ... day. Privately-held company Chiesi doesn’t
Chiesi’s Holoclar is another groundbreaking ATMP, a stem cell replacement therapy for patients with the rare blindness condition limbal stem cell deficiency, which gained European approval in 2015. ... Giorgio Iotti, head of programme leadership and
First to market in Europe was Chiesi with its Trimbow (formoterol fumarate, glycopyrronium and beclomethasone) product, although this has to be administered twice-daily while Trelegy and PT010 are dosed just
More from news
Approximately 16 fully matching, plus 29 partially matching documents found.
GSK, AZ and Chiesi are each playing in this new market.
911. The Medicines Company/ Chiesi. Product acquisition. Acquisition of cardiovascular assets Cleviprex, Kengreal and rights to Argatroban.
The technology was licensed from the Dutch bio company uniQure BV by Chiesi, a mid-sized, family-owned pharma company based in Parma, Italy. ... Paolo Chiesi, chairman of the board of directors, and Andrea Chiesi, CEO of Chiesi Farmaceutici, are part of
Cornerstone Therapeutics/ Chiesi Farmaceutici. Acquisition (42 per cent). US speciality pharmaceutical company focused hospital and niche respiratory products. ... 2. Global rights excluding India, Pakistan and China. 3. Acquisition of the shares not
In keeping with Chiesi's marketing capabilities, the licence is for certain countries, including Europe, Turkey and CIS countries. ... 58. †Veloxis Pharmaceuticals / Chiesi Farmaceutici. Licence. LCP-Tacro (tacrolimus) immunosuppressant for kidney
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Dr Paolo Chiesi, chairman of the board at Holostem, said: “On behalf of the Holostem board, I am delighted to welcome Richard to the company.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...